Assenagon Asset Management S.A. Morphic Holding, Inc. Transaction History

Assenagon Asset Management S.A.

$37.1 Billion
Q1 2024

A detailed history of Assenagon Asset Management S.A. transactions in Morphic Holding, Inc. stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 71,384 shares of MORF stock, worth $2.43 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

71,384

Previous 97,422 26.73%

Holding current value

$2.43 Million

Previous $2.81 Million 10.7%

% of portfolio

0.01%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 24, 2024	SELL	$26.64 - $40.31 $693,652 - $1.05 Million	-26,038 Reduced 26.73%	71,384 $2.51 Million
Q4 2023 Jan 17, 2024	SELL	$19.95 - $31.0 $416,456 - $647,125	-20,875 Reduced 17.65%	97,422 $2.81 Million
Q3 2023 Nov 06, 2023	BUY	$21.33 - $59.42 $1.1 Million - $3.06 Million	51,521 Added 77.15%	118,297 $2.71 Million
Q2 2023 Jul 25, 2023	BUY	$34.33 - $62.11 $908,989 - $1.64 Million	26,478 Added 65.71%	66,776 $3.83 Million
Q1 2023 Apr 18, 2023	SELL	$26.01 - $48.69 $1.88 Million - $3.52 Million	-72,290 Reduced 64.21%	40,298 $1.52 Million

Q4 2022 Jan 12, 2023	BUY	$24.14 - $30.37 $955,533 - $1.2 Million	39,583 Added 54.22%	112,588 $3.01 Million
Q3 2022 Oct 27, 2022	SELL	$22.23 - $33.37 $5.28 Million - $7.93 Million	-237,651 Reduced 76.5%	73,005 $2.07 Million
Q2 2022 Jul 27, 2022	BUY	$19.74 - $43.01 $5.02 Million - $10.9 Million	254,101 Added 449.3%	310,656 $6.74 Million
Q1 2022 Apr 25, 2022	SELL	$36.25 - $52.02 $609,326 - $874,404	-16,809 Reduced 22.91%	56,555 $2.27 Million
Q4 2021 Feb 01, 2022	BUY	$43.27 - $65.72 $3.17 Million - $4.82 Million	73,364 New	73,364 $3.48 Million

Others Institutions Holding MORF

# of Institutions

142

Shares Held

37.9M

Call Options Held

13.5K

Put Options Held

190K

View Full List

About Morphic Holding, Inc.

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $1.31B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

More about MORF

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Assenagon Asset Management S.A. with notifications on news.

Account

Assenagon Asset Management S.A. Morphic Holding, Inc. Transaction History